Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea

Allergan

Status: Completed

Conditions: Retinal Vein Occlusion

Treatments: Drug: dexamethasone 700 ㎍ intravitreal implant

Study type: Observational

Funder types: Industry

Identifiers

NCT01976650

206207-029

Details and patient eligibility

About

This study is a Post-Market Surveillance study in Korea to evaluate the safety and efficacy of dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant used to treat Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye in clinical practice.

Enrollment: 724 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye treated with (OZURDEX®) in clinical practice.

Exclusion criteria

• Patients with eye infections
• Patients with glaucoma.

Trial design

724 participants in 1 patient group

OZURDEX®

Description:

Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.

Treatment:

Drug: dexamethasone 700 ㎍ intravitreal implant